Literature DB >> 3137276

Effect of interferon-gamma treatment on the course of a burn wound infection.

M J Hershman1, G Sonnenfeld, W A Logan, J D Pietsch, S R Wellhausen, H C Polk.   

Abstract

Interferon-gamma (IFN-gamma) has been shown to have immunoregulatory properties and is able to modulate resistance to several microbial infections. This study was designed to determine the efficacy of IFN-gamma treatment in a murine burn wound infection model. Bacterial challenge consisted of Klebsiella pneumoniae (10(8) organisms/ml) or Pseudomonas aeruginosa (10(8) organisms/ml), applied topically immediately after burning. Groups of CBA/J mice received either IFN-gamma or RPMI-1640 medium (controls) subcutaneously. IFN-gamma was administered daily at a dose of 7,500 units for 5 days prior to bacterial challenge. Burn without bacterial challenge produced no mortality. Mice treated with IFN-gamma survived significantly longer than controls when the bacterial challenge was K. pneumoniae. There was no difference in survival when bacterial challenge was P. aeruginosa. The Ia antigen expression of peripheral blood mononuclear cells was severely reduced for 3 days post-burn. This drop was prevented on day 3 post-burn in mice treated with IFN-gamma. These data indicate that interferon was effective treatment in a murine model of Klebsiella burn wound infection and was associated with maintenance of Ia antigen expression that may have contributed to the action of the IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137276     DOI: 10.1089/jir.1988.8.367

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  2 in total

Review 1.  Animal models in interferon research: some current trends.

Authors:  H Schellekens
Journal:  Experientia       Date:  1989-06-15

2.  Rationale, design and performance of a clinical trial to investigate interferon-gamma (Imukin) in the prophylactic treatment of severe burns-related infections.

Authors:  J D Ioannovich; R D Hinzmann; G Deichsel; G G Steinmann
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.